Overview

Nexium Dyspepsia/AST

Status:
Completed
Trial end date:
2005-01-01
Target enrollment:
0
Participant gender:
All
Summary
The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Esomeprazole
Criteria
Inclusion Criteria:

- At least 3 months of symptoms of pain or burning centered in the upper abdomen prior
to enrollment.

- Helicobacter pylori test performed at enrollment must be negative (Helicobacter pylori
is a bacterial infection of the stomach).

Exclusion Criteria:

- Patients with symptoms of other gastrointestinal diseases, such as Gastroesophageal
Reflux Disease (GERD), Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease
(IBD).

- Helicobacter pylori eradication treatment during the last 12 months prior to
enrollment.